Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation

References

• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109:S2–S26.
   PubMed Web of Science ®Google Scholar
• Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther. 2014;39:1033–1042.
   PubMed Web of Science ®Google Scholar
• Sommer F, Bäckhed F. The gut microbiota–masters of host development and physiology. Nat Rev Microbiol. 2013;11:227–238.
   PubMed Web of Science ®Google Scholar
• Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43:37–49.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506.
   PubMed Web of Science ®Google Scholar
• Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139–142.
   PubMed Web of Science ®Google Scholar
• Pyleris E, Giamarellos-Bourboulis EJ, Pistiki A, et al. Intestinal overgrowth in irritable bowel syndrome. Presented at: United European Gastroenterology Week; 2012 Oct 20–24; Amsterdam, the Netherlands.
   Google Scholar
• Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–419.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Funari V, Giamarellos-Bourboulis EJ, et al. The first large scale deep sequencing of the duodenal microbiome in irritable bowel syndrome reveals striking differences compared to healthy controls. Gastroenterology. 2013;144:S–59.
   Google Scholar
• Si J-M, Yu Y-C, Fan YJ, et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol. 2004;10:1802–1805.
   PubMed Web of Science ®Google Scholar
• Mättö J, Maunuksela L, Kajander K, et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol. 2005;43:213–222.
   PubMed Web of Science ®Google Scholar
• Bradley HK, Wyatt GM, Bayliss CE, et al. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol. 1987;23:29–32.
   PubMed Web of Science ®Google Scholar
• Malinen E, Rinttilä T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100:373–382.
   PubMed Web of Science ®Google Scholar
• Maukonen J, Mättö J, Satokari R, et al. PCR DGGE and RT-PCR DGGE show diversity and short-term temporal stability in the Clostridium coccoides-Eubacterium rectale group in the human intestinal microbiota. FEMS Microbiol Ecol. 2006;58:517–528.
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Weber J, Loening-Baucke V, et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005;43:3380–3389.
   PubMed Web of Science ®Google Scholar
• Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24–33.
   PubMed Web of Science ®Google Scholar
• Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321–1329.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Tang J, Pyleris E, et al. Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2015;50:1076–1087.
   PubMed Web of Science ®Google Scholar
• Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome–a meta-analysis. Am J Gastroenterol. 2006;101:1894–1899.
   PubMed Web of Science ®Google Scholar
• Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:535–544.
   PubMed Web of Science ®Google Scholar
• Jalanka J, Salonen A, Fuentes S, et al. Microbial signatures in post-infectious irritable bowel syndrome toward patient stratification for improved diagnostics and treatment. Gut Microbes. 2015;6:364–369.
   PubMed Web of Science ®Google Scholar
• Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower Bifidobacteria counts in both duodenal mucosa- associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009;15:2887–2892.
   PubMed Web of Science ®Google Scholar
• Jiang Z-D, Ke S, Dupont HL. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents. 2010;35:278–281.
   PubMed Web of Science ®Google Scholar
• Brown EL, Xue Q, Jiang Z-D, et al. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother. 2010;54:388–396.
   PubMed Web of Science ®Google Scholar
• Hirota SA. Understanding the molecular mechanisms of rifaximin in the treatment of gastrointestinal disorders - a focus on the modulation of host tissue function. Mini Rev Med Chem. 2015;16:206–217.
   PubMed Web of Science ®Google Scholar
• Cheng J, Shah YM, Ma X, et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther. 2010;335:32–41.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Distrutti E, Mencarelli A, et al. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivityand protects against inflammation in a rodent model of colitis. Digestion. 2002;66:246–256.
   PubMed Web of Science ®Google Scholar
• Brigidi P, Swennen E, Rizzello F, et al. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother. 2002;14:290–295.
   PubMed Web of Science ®Google Scholar
• Maccaferri S, Vitali B, Klinder A, et al. Rifaximin modulates the colonic microbiota of patients with Crohn’s disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother. 2010;65:2556–2565.
   PubMed Web of Science ®Google Scholar
• Fedorak RN. Understanding why probiotic therapies can be effective in treating IBD. J Clin Gastroenterol. 2008;42:S111–S115.
   PubMed Web of Science ®Google Scholar
• Ventura M, O’Flaherty S, Claesson MJ, et al. Genome-scale analyses of health-promoting bacteria: probiogenomics. Nat Rev Microbiol. 2009;7:61–71.
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731–16736.
   PubMed Web of Science ®Google Scholar
• Xu D, Gao J, Gillilland M 3rd, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146:484–496.
   PubMed Web of Science ®Google Scholar
• Zareie M, Johnson-Henry K, Jury J, et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut. 2006;55:1553–1560.
   PubMed Web of Science ®Google Scholar
• Borruel N, Carol M, Casellas F, et al. Increased mucosal tumour necrosis factor alpha production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut. 2002;51:659–664.
   PubMed Web of Science ®Google Scholar
• Llopis M, Antolin M, Carol M, et al. Lactobacillus casei downregulates commensals’ inflammatory signals in Crohn’s disease mucosa. Inflamm Bowel Dis. 2009;15:275–283.
   PubMed Web of Science ®Google Scholar
• Thomas CM, Hong T, van Pijkeren JP, et al. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS One. 2012;7:e31951.
   PubMed Web of Science ®Google Scholar
• Ait-Belgnaoui A, Han W, Lamine F, et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut. 2006;55:1090–1094.
   PubMed Web of Science ®Google Scholar
• Soldi S, Vasileiadis S, Uggeri F, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015;8:309–325.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Scaldaferri F, Petito V, et al. The role of antibiotics in gut microbiota modulation: the eubiotic effects of rifaximin. Dig Dis. 2016;34:269–278.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557–563.
   PubMed Web of Science ®Google Scholar
• Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326–333.
   PubMed Web of Science ®Google Scholar
• Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52:89–95.
   PubMedGoogle Scholar
• Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25:781–786.
   PubMed Web of Science ®Google Scholar
• Yang J, Lee H-R, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53:169–174.
   PubMed Web of Science ®Google Scholar
• Lembo A, Zakko SF, Ferreira NL, et al. Rifaximin for the treatment of diarrhea associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology. 2008;134:A–545.
   Google Scholar
• Peralta S, Cottone C, Doveri T, et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with rifaximin. World J Gastroenterol. 2009;15:2628–2631.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, et al.; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Tana P, Mengoli C, et al. Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome. Intern Emerg Med. 2011;6:403–411.
   PubMed Web of Science ®Google Scholar
• Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther. 2012;36:1084–1093.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59:1278–1285.
   PubMed Web of Science ®Google Scholar
• Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107:28–35.
   PubMed Web of Science ®Google Scholar
• Kim M-S, Morales W, Hani AA, et al. The effect of rifaximin on gut flora and Staphylococcus resistance. Dig Dis Sci. 2013;58:1676–1682.
   PubMed Web of Science ®Google Scholar
• Pistiki A, Galani I, Pyleris E, et al. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents. 2014;43:236–241.
   PubMed Web of Science ®Google Scholar
• Darkoh C, Lichtenberger LM, Ajami N, et al. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother. 2010;54:3618–3624.
   PubMed Web of Science ®Google Scholar
• Posserud I, Stotzer P-O, Björnsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802–808.
   PubMed Web of Science ®Google Scholar
• Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012;55:S65–S70.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Barrett AC, Bortey E, et al. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Aliment Pharmacol Ther. 2015;41:39–45.
   PubMed Web of Science ®Google Scholar
• Kimer N, Krag A, Gluud LL. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Prefer Adherence. 2014 18;8:331–338.
   PubMed Web of Science ®Google Scholar
• Clin Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Gastroenterol Hepatol. 2014;12:1390–1397.
   Web of Science ®Google Scholar
• Tabibian JH, Gossard A, El-Youssef M, et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther. 2014 Jun 9. doi:10.1097/MJT.0000000000000102.
   PubMedGoogle Scholar
• Prantera C, Lochs H, Grimaldi M, et al.; Retic Study Group (Rifaximin-Eir Treatment in Crohn’s Disease). Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn’s disease. Gastroenterology. 2012;142:473–481.
   PubMed Web of Science ®Google Scholar
• Flores J, Dupont HL, Jiang Z-D, et al. A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers’ diarrhea in Mexico during the dry season. J Travel Med. 2011;18:333–336.
   PubMed Web of Science ®Google Scholar
• Sanyal AMK, Bass NM, Frederick T, et al. Rates of commonly occurring infections in cirrhosis patients remain stable during long-term rifaximin treatment. J Hepatol. 2012;56:S255–S256.
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Reddy KR, Wong F, et al. Long-term antibiotic and proton-pump inhibitor use are strong predictors of recurrent infections in cirrhosis: a prospective multi-center study from NACSELD. J Hepatol. 2013;58:S97.
   Web of Science ®Google Scholar
• Tandon P, Delisle A, Topal JE, et al. High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol. 2012;10:1291–1298.
   PubMed Web of Science ®Google Scholar
• Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–1081.
   PubMed Web of Science ®Google Scholar
• Mattila E, Arkkila P, Mattila PS, et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013;37:122–128.
   PubMed Web of Science ®Google Scholar
• Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study (TARGET3). Available from: https://clinicaltrials.gov/ct2/show/results/NCT01543178?sect=X4370156#othr
   Google Scholar
• Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39:1161–1168.
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal con-centration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44:2205–2206.
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51:36–66.
   PubMed Web of Science ®Google Scholar
• De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res. 1986;12:979–981.
   PubMedGoogle Scholar
• DuPont HL, Jiang Z-D. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect. 2004;10:1009–1011.
   PubMed Web of Science ®Google Scholar
• Kothary V, Scherl EJ, Bosworth B, et al. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother. 2013;57:811–817.
   PubMed Web of Science ®Google Scholar
• Valentin T, Leitner E, Rohn A, et al. Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect. 2011;62:34–38.
   PubMed Web of Science ®Google Scholar
• Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol. 2011;4:43–48.
   PubMedGoogle Scholar
• Finegold SM, Molitoris D, Vaisanen M-L. Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrob Agents Chemother. 2009;53:281–286.
   PubMed Web of Science ®Google Scholar
• Trapnell CB, Connolly M, Pentikis H, et al. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother. 2007;41:222–228.
   PubMed Web of Science ®Google Scholar
• Pentikis HS, Connolly M, Trapnell CB, et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy. 2007;27:1361–1369.
   PubMed Web of Science ®Google Scholar
• Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2013;17:1314–1320.
   PubMed Web of Science ®Google Scholar
• Blandizzi C, Viscomi GC, Marzo A, et al. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. Pharmacol Res. 2014;85:39–44.
   PubMed Web of Science ®Google Scholar